Insogna KL, et al. - In this report, researchers summarized the results from a double-blind, placebo-controlled, phase 3 trial of burosumab in symptomatic adults with X-linked hypophosphatemia (XLH). Burosumab treatment vs placebo resulted in a significant increase in biochemical markers of bone formation and resorption from baseline. Burosumab displayed safety profile similar to placebo. No treatment-related serious adverse events or meaningful changes from baseline in serum or urine calcium, intact parathyroid hormone, or nephrocalcinosis were noted. Burosumab was thus supported to be a novel therapeutic addressing an important medical need in adults with XLH.